Literature DB >> 11479281

The structure of the lipooligosaccharide (LOS) from the alpha-1,2-N-acetyl glucosamine transferase (rfaK(NMB)) mutant strain CMK1 of Neisseria meningitidis: implications for LOS inner core assembly and LOS-based vaccines.

M M Rahman1, C M Kahler, D S Stephens, R W Carlson.   

Abstract

The inner core structures of the lipooligosaccharides (LOS) of Neisseria meningitidis are potential vaccine candidates because both bactericidal and opsonic antibodies can be generated against these epitopes. In an effort to better understand LOS biosynthesis and the potential immunogenicity of the LOS inner core, we have determined the LOS structure from a meningococcal rfaK mutant CMK1. The rfaK gene encodes the transferase that adds an alpha-N-acetylglucosaminosyl residue to O-2 of the inner core heptose (Hep) II of the LOS. The LOS oligosaccharide from this mutant was previously shown to contain only Hep, 3-deoxy-D-manno-2-octulosonic acid (Kdo), and multiple phosphoethanolamine (PEA) substituents (Kahler et al., 1996a, J. Bacteriol., 178, 1265-1273). The complete structure of the oligosaccharide (OS) component of the LOS from mutant CMK1 was determined using glycosyl composition and linkage analyses, and 1H, 13C, and 31P nuclear magnetic resonance spectroscopy. The CMK1 OS structure contains a PEA group at O-3 of Hep II in place of the usual glucosyl residue found at this position in the completed L2 LOS glycoform from the parent NMB strain. The PEA group at O-6 of Hep II, however, is present in both the CMK1 mutant LOS and parental NMB L2 LOS structures. The structure of the OS from CMK1 suggests that PEA substituents are transferred to both the O-3 and O-6 positions of Hep II prior to: (1) the incorporation of the alpha-GlcNAc on Hep II; (2) the synthesis of the alpha-chain on Hep I; and (3) the substitution of the glycosyl residue at the O-3 Hep II, which distinguishes L2 and L3 immunotypes. The LOS structure of the CMK1 mutant makes it a candidate immunogen that could generate broadly cross-reactive inner-core LOS antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479281     DOI: 10.1093/glycob/11.8.703

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  5 in total

Review 1.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Phenotypic and transcriptional characterization of the meningococcal PhoPQ system, a magnesium-sensing two-component regulatory system that controls genes involved in remodeling the meningococcal cell surface.

Authors:  J Newcombe; J C Jeynes; E Mendoza; J Hinds; G L Marsden; R A Stabler; M Marti; J J McFadden
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

3.  An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2.

Authors:  Lingbing Kong; Balakumar Vijayakrishnan; Michael Kowarik; Jin Park; Alexandra N Zakharova; Larissa Neiwert; Amirreza Faridmoayer; Benjamin G Davis
Journal:  Nat Chem       Date:  2016-02-01       Impact factor: 24.427

4.  Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.

Authors:  Pablo Bonvehí; Dominique Boutriau; Javier Casellas; Vincent Weynants; Christiane Feron; Jan Poolman
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

5.  Attachment and invasion of Neisseria meningitidis to host cells is related to surface hydrophobicity, bacterial cell size and capsule.

Authors:  Stephanie N Bartley; Yih-Ling Tzeng; Kathryn Heel; Chiang W Lee; Shakeel Mowlaboccus; Torsten Seemann; Wei Lu; Ya-Hsun Lin; Catherine S Ryan; Christopher Peacock; David S Stephens; John K Davies; Charlene M Kahler
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.